Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,760 across all filing types
Latest filing 2024-08-30 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings
2024-08-30 English
Intimation of Loss of Share Certificate
Regulatory Filings
2024-08-30 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange's listing department, notifying them about the issuance of duplicate share certificates. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about share certificate issuance and does not contain financial data, earnings, management changes, or meeting materials. It is an official regulatory communication related to share certificates but does not fit into categories like share issue, capital change, or director dealings. Given the nature and length (1969 characters), it is not a report or announcement of a report but a regulatory filing informing the exchange of a compliance matter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-08-30 English
Intimation of Issue of Duplicate Share Certificates
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the issuance of duplicate share certificates. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about share certificate issuance and does not contain financial data, earnings, management changes, or meeting materials. It is an announcement related to share certificates, which falls under capital changes but specifically about duplicate certificates rather than new share issues or capital restructuring. The closest fitting category is Share Issue/Capital Change (SHA), as it deals with share certificate issuance and related capital documentation. The document length is short and it is not a report or a certification, so it is not RPA or RNS. Therefore, the classification is SHA with high confidence.
2024-08-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the USFDA inspection outcome for a manufacturing facility, stating the inspection was closed with a Voluntary Action Indicated (VAI) classification. The document is brief (1513 characters), does not contain financial data or detailed report content, and serves as an update or announcement to the exchange. It is not a full report like an Annual Report, Interim Report, or Audit Report. It is also not a certification or voting result. Given the short length and nature as an announcement of an event related to regulatory inspection, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-08-30 English
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the USFDA inspection outcome for a manufacturing facility, stating the inspection was closed with a Voluntary Action Indicated (VAI) classification. The document is brief (1513 characters), contains no financial data or detailed report, and serves as an update or announcement to the exchange. It does not contain an annual or interim report, audit report, or any detailed financial or management information. It is an announcement of a regulatory event related to compliance and inspection results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.